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In recent years, global health analysts and actors have considered the impact of prioritization of HIV/AIDS control on other health agendas, including health systems strengthening. Many individuals directly involved with HIV/AIDS control have argued that the impact largely has been positive, generating greater attention to and resources not just for HIV/AIDS but for all health issues. 2, 3 Others, concerned about a large concentration of resources on a disease that represents a high but not dominant burden-5.7% of all deaths in lowincome countries 4 -have pointed to adverse effects on other health issues 1, 5 and to imbalances in resource allocation. [6] [7] [8] In this article, we examine one facet of this question: the impact of international aid for HIV/AIDS control on donor funding for other health issues that affect low-income countries. There are other dimensions to the issue, such as the impact of attention to HIV/AIDS on human resources in low-income countries, the effect on country reporting systems, and the consequences for national resource allocations. We avoid drawing inferences on these dimensions given the particular focus of our study.
We note from the outset that any answers to the question we ask must be tentative. The question implicitly involves a counterfactual: In the absence of the HIV/AIDS epidemic, what would have happened to international funding for other health issues? Many HIV/AIDS activists are certain such funding would have been lower; many advocates for other health issues are convinced it would have been higher. In reality, we cannot know the answer with certainty because we cannot rerun history and compare donor funding trends for health in the absence of the epidemic with those in the real world where the epidemic exists. All inferences that we make-or that anyone else makes-must be interpreted in that light.
METHODS
We calculated the amount of funding for major health and population issues in constant US dollars from bilateral and multilateral donors. We analyzed the decade 1998-2007 because records for these but not earlier or later years were relatively comprehensive for each of the donors considered (this article updates a similar analysis by Shiffman 9 that considered funding data only through 2005). We relied on the Credit Reporting System (CRS) 10 database of the Organization for Economic Cooperation and Development's Development Assistance Committee, an organization that monitors and assesses aid from the world's major bilateral and multilateral donors. CRS categories 120 and 130 cover health and population funding and include commitments from the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President's Emergency Plan for AIDS Relief (PEPFAR). These categories are divided into 17 subcategories. In addition, since 2004, the CRS has included a subcategory called ''social mitigation of HIV/AIDS'' that was not previously among these health and population categories. We grouped these subcategories into 4 broad health agendas that historically have been prominent among donors: HIV/AIDS prevention and control, population and reproductive health, the control of infectious diseases other than HIV/AIDS, and health systems strengthening. We then examined annual funding figures, comparing HIV/AIDS trends with those of the other agendas. HIV/AIDS encompasses purpose code 13040 (STD control, including HIV/AIDS) and 16064 (social mitigation of HIV/AIDS); population and reproductive health includes purpose codes 13010 (population policy and administrative management), 13020 (reproductive health care), 13030 (family planning), and 13081 (personnel development for population and reproductive health); infectious diseases consists of purpose codes 12250 (infectious disease control), 12262 (malaria control), and 12263 (tuberculosis control); and health systems strengthening comprises purpose codes 12110 (health policy and administrative management), 12181 (medical education/training), 12182 (medical research), 12191 (medical services), 12220 (basic health care), 12230 (basic health infrastructure), 12240 (basic nutrition), 12261 (health education), and 12281 (health personnel development).
CRS data have a number of well-known limitations. Among these are the fact that the database is not fully complete as donors do not report all grants and loans; each grant is assigned to only a single category according to its primary purpose, even if it includes funding for multiple issues; disbursements are not as well covered in the CRS as commitments, so most analyses are done on the latter; and the category for HIV/AIDS also includes funding for the control of other sexually transmitted infections. This being said, the CRS in recent years has been relatively complete (the CRS user guide estimates that coverage ratios for commitments were 90% by 2000 11 ), and there is no reason to believe that reporting omissions vary systematically by issue, so comparisons across issues may be reasonably reliable. 9 Also, other studies have concluded that nearly all funding in the STD/HIV category is for HIV/AIDS, and even funding geared toward the control of other sexually transmitted infections is likely to benefit HIV/AIDS prevention and control. 12 
RESULTS

Relative Aid Shares: 1998-2007
The percentage of funding for HIV/AIDS rose rapidly over the decade, from just 5.5% of total health and population commitments in 1998 to nearly half of all commitments-47.2%-in 2007 (Table 1, Fig. 1 ). The percentage for other infectious diseases, including tuberculosis and malaria, also rose considerably-from 5.8% to 16.7%. Putting these two categories together, we see that infectious disease control, including that for HIV/AIDS, came to dominate donor funding for health across the decade, rising from just about one tenth of such aid in 1998 to nearly two thirds of all aid in 2007. During the same period, the shares for population and for health systems strengthening declined precipitously-for population from 26.4% to 12.3% and for health systems strengthening from 62.3% to 23.9%.
Absolute Aid Shares: 1998-2007
It is also worth examining absolute aid shares, as growth in total health aid may have benefited all health issues despite the decline in relative shares for some. Table 2 indicates that total funding for health nearly tripled over this period, from US $5.5 billion in 1998 to US $15.6 billion in 2007. HIV/AIDS funding grew at a dramatic pace, from just US $304 million in 1998 to US $7.4 billion in 2007, an average annual growth rate of 48.1% (Tables 2, 3 ). Funding for other infectious diseases also grew rapidly, although not at the same pace as that for HIV/AIDS-from US $319 million in 1998 to US $2.6 billion in 2007-an average annual growth rate of 30.8%.
Funding for population and for health systems strengthening also grew in aggregate terms, although at a much slower pace. Between 1998 and 2007, funding for population increased from US $1.5 billion to US $1.9 billion at an average annual growth rate of 9.5%, and that for health systems strengthening grew from US $3.4 billion to US $3.7 billion at an average annual growth rate of 2.7% (Tables 2, 3) . For both population and health systems strengthening, average annual growth in aid was far slower than for donor aid for all issues, which grew at a pace of 11.6% per annum over the decade, and for all health and population aid, which grew at a pace of 13.2% (Table 3) .
If we put funding trends for HIV/AIDS and health systems strengthening together in one chart (Fig. 2) , we see that the dominant dynamic of the decade is one of rapid 
Trends Since 2008
The CRS is up to date only through 2007. During the past several years, and especially during 2008 and 2009, there has been a marked increase in attention to the issue of health systems strengthening, at least at the level of discourse. Funding windows to support health systems strengthening have opened at a pair of the largest global health initiativesthe Global Fund for AIDS, Tuberculosis and Malaria and the GAVI Alliance. 13, 14 Two foundations-the Rockefeller Foundation and the Doris Duke Charitable Foundation-have made this issue a priority. 15, 16 PEPFAR has indicated that it will increase support for the strengthening of health systems. 17 The World Health Organization lists this issue as one of its top priorities. 18 At the same time, it seems that funding for HIV/AIDS will continue to rise. The Obama Administration announced on May 5, 2009 , that it will propose to Congress a global health budget of US $63 billion over 6 years from 2009 to 2014. 19 The administration proposed that PEPFAR receive more than 70% of this. In federal year 2009, PEPFAR constituted US $6.49 billion, or four fifths, of the US $8.186 billion US global health initiative total. The proposed budget for federal year 2010 has PEPFAR receiving US $6.655 billion or 77% of the total.
No comprehensive data are available to determine relative and aggregate shares of all donor aid for these major health issues through 2008 and 2009. Will the professed concern by these major global health organizations translate into a rebalancing of resources in favor of health systems strengthening and other agendas? Or will this be only a shift in discourse and will HIV/AIDS continue to dominate funding? Follow-up studies will be necessary to assess this question and to monitor trends.
CONCLUSIONS
Aid for HIV/AIDS may have lifted some health funding boats. Funding for HIV/AIDS has risen dramatically during the past decade; concurrently, funding for the control of other infectious diseases has risen as well, although not as rapidly as funding for HIV/AIDS. This is an association and does not demonstrate causality. However, it may well be the case that the rise in attention to HIV/AIDS is causally connected to the rise in funding for other infectious diseases. For instance, one might ask whether the establishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria-which has dramatically increased funding not just for the first eponymous disease but also for the others-would have been possible without advocacy to address AIDS itself.
However, the data indicate that HIV/AIDS has not lifted all boats-and may actually have caused leaks to spring in some. In particular, funding for health systems strengthening has largely stagnated during the decade; funding for population has grown at a pace far slower than that for all donor aid. Again, these are associations, not proven causal relationships. However, the truth of any contention that HIV/AIDS funding has benefited the agendas for health systems strengthening and for population and reproductive health would have to be revealed in ways that go beyond analysis of donor funding trends, which do not support such a claim. 
